The strong beat and reaffirmed guidance reinforce confidence in commercial execution and the path to 2027 profitability. Traders should focus on the two PDUFA dates (Aug 23 for DTX401 and Sep 19 for UX111) and the GTX-102 Phase 3 readout as binary catalysts that could significantly impact the stock.
Drugs in focus
RARE drug pipeline →Evkeeza
● Neutral Named in this 8-K- Impact
- Phase
- Approved
- Time to market
- Already approved and commercialized since February 2021 (US) and June 2021 (EU). Latest label expansion (ages 1-5) approved September 2025.
- Next catalyst
- None dated
What to watchEvkeeza is a first-in-class ANGPTL3 inhibitor approved for an ultra-rare cholesterol disorder (HoFH, ~1,300 US patients). It is already de-risked by FDA approval but contributes only ~$130-150M in annual US sales versus Regeneron's ~$14.3B total revenue. The stock is primarily driven by Dupixent, EYLEA, and the broader pipeline, not this one drug. Watch quarterly Evkeeza US sales for gradual label-expansion uptake, but do not expect binary swings from this asset.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 5 $24.93entry
- T+1 · 3mo ago +3.57%α +3.73% · $25.82
- T+5 · 3mo ago +7.74%α +7.39% · $26.86
- T+20 · 3mo ago +6.42%α +7.02% · $26.53
- T+60 · 19d ago −32.69%α −32.64% · $16.78
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Ultragenyx reported Q2 2026 revenue of $214M (beat $183.1M consensus by 17%, +28% YoY) and EPS of -$0.90 (beat -$1.00 consensus by 10%, narrowed from -$1.17 YoY). All products showed strong growth, full-year 2026 guidance was reaffirmed, and management reiterated its path to profitability in 2027. The company highlighted upcoming H2 catalysts: two PDUFA dates (DTX401 gene therapy Aug 23, UX111 gene therapy Sep 19) and GTX-102 Phase 3 Angelman data in Sep/Oct.
Key Financial Metrics
Key Facts
- Q2 2026 total revenue $214M, up 28% YoY from $167M
- EPS -$0.90 vs consensus -$1.00 (10% beat) and vs -$1.17 YoY
- Crysvita revenue $156M (+29% YoY), Dojolvi $27M (+17%), Evkeeza $21M (+50%), Mepsevii $10M (+11%)
- Net loss narrowed to $92M from $115M YoY
- Cash, equivalents, and marketable securities $436M at June 30, down from $737M at Dec 31, 2025
- Reaffirmed FY2026 total revenue guidance $730M-$760M and combined R&D+SG&A expenses flat to slightly down vs 2025
- Upcoming catalysts: DTX401 PDUFA Aug 23, UX111 PDUFA Sep 19, GTX-102 Phase 3 data in Sep/Oct
- Net cash used in operations $97M in Q2
Financial Impact
Revenue beat consensus by $30.9M (17%) and EPS beat by $0.10 (10%) with gross margin of approximately 84%
Risk Factors
- Cash burn continues: cash dropped $301M from Dec 2025 to $436M, raising potential need for future financing
- DTX401 and UX111 approvals not guaranteed; FDA could require additional data or manufacturing changes
- GTX-102 Phase 3 Angelman syndrome readout is a high-risk binary event
- Dependence on Kyowa Kirin for Crysvita commercialization and supply in major markets
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-332802 |
| Document: 0001193125-26-332802-index.html | 0001193125-26-332802 |
| Document: 0001193125-26-332802.txt | 0001193125-26-332802 |
| 8-K Data (Synthetic) | 0001193125-26-332802 |
Track record
22 reports on RARE
7 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +48.73% at T+60 after the Apr 2, 2026 report. 8 of 9 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $16.08 Now $15.90 −1.12% settles Nov 20
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $16.14 Now $15.90 −1.49% settles Nov 17
- Nov 3, 202613d ago 8-K Mixed 6/10 No price data
- Nov 3, 202613d ago Press Release Bearish 6/10 Entry $17.16 to $16.70 Now $15.90 +7.34% ▲ +2.68% +1.77% vs SPY
- Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $16.10 to $15.43 Now $15.90 −1.24% ▼ −4.16% −1.46% vs SPY
- Oct 20, 202627d ago SC 13G Neutral 3/10 Entry $15.92 to $16.75 Now $15.90 −0.13% ▲ +5.21% +5.66% vs SPY
- Oct 19, 202628d ago 8-K Neutral 4/10 Entry $15.07 to $16.08 Now $15.90 +5.51% ▲ +6.70% +6.85% vs SPY
- Oct 14, 20264w ago 8-K Bullish 6/10 Entry $14.90 to $15.92 Now $15.90 +6.71% ▲ +6.85% +6.39% vs SPY
- Oct 7, 20265w ago 8-K Bullish 6/10 Entry $14.89 to $14.90 Now $15.90 +6.78% ▲ +0.07% +1.05% vs SPY
- Sep 17, 20268w ago Press Release Bullish 8/10 Entry $14.50 to $14.77 Now $15.90 +9.66% ▲ +1.86% +1.01% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers